NCT06248632View on ClinicalTrials.gov

Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets FLAM-XLH

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
X-Linked Hypophosphatemic Rickets
Interventions
OTHER

Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)

Expression of inflammatory markers obtained from circulating monocytic cells of XLH

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT06248632 - Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets FLAM-XLH | Biotech Hunter | Biotech Hunter